Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 3	NOV 26	MARPAT enhanced with FSORT command
NEWS 4	NOV 26	CHEMSAFE now available on STN Easy
NEWS 5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 6	DEC 01	ChemPort single article sales feature unavailable
NEWS 7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 14	FEB 10	COMPENDEX reloaded and enhanced
NEWS 15	FEB 11	WTEXTILES reloaded and enhanced
NEWS 16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:54:54 ON 10 MAR 2009

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 09:55:12 ON 10 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 MAR 2009 HIGHEST RN 1117698-24-4
DICTIONARY FILE UPDATES: 8 MAR 2009 HIGHEST RN 1117698-24-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10585603\10585603a.str



chain nodes :
10 11 12 13 20 21 22 23 24 25
ring nodes :
1 2 3 4 5 6 7 8 9 14 15 16 17 18 19
chain bonds :
3-10 9-25 10-11 10-24 11-12 12-13 12-23 13-14 15-22 17-21 18-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 14-15 14-19 15-16 16-17 17-18
18-19
exact/norm bonds :
1-2 1-6 2-3 3-4 3-10 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-24 11-12 12-23
exact bonds :
9-25 12-13 13-14 15-22 17-21 18-20
normalized bonds :
14-15 14-19 15-16 16-17 17-18 18-19

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS

Stereo Bonds:

23-12 (Single Wedge).

Stereo Chiral Centers:

12 (Parity=Don't Care)

Stereo RSS Sets:

Type=Relative (Default). 1 Nodes= 12

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 09:55:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 09:55:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L3            0 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10585603\10585603b.str
```



chain nodes :
10 11 12 13 20 21 22 23 24 25
ring nodes :
1 2 3 4 5 6 7 8 9 14 15 16 17 18 19
chain bonds :
3-10 9-25 10-11 10-24 11-12 12-13 12-23 13-14 15-22 17-21 18-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 14-15 14-19 15-16 16-17 17-18
18-19
exact/norm bonds :
1-2 1-6 2-3 3-4 3-10 4-5 5-6 5-7 6-9 7-8 8-9 10-24 12-23
exact bonds :
9-25 10-11 11-12 12-13 13-14 15-22 17-21 18-20
normalized bonds :
14-15 14-19 15-16 16-17 17-18 18-19

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS

Stereo Bonds:

23-12 (Single Wedge).

Stereo Chiral Centers:

12 (Parity=Don't Care)

Stereo RSS Sets:

Type=Relative (Default). 1 Nodes= 12

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l4
SAMPLE SEARCH INITIATED 09:56:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       13 TO ITERATE

100.0% PROCESSED       13 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           44 TO      476
PROJECTED ANSWERS:               3 TO      163

L5            3 SEA SSS SAM L4

=> d scan

L5   3 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   Peptidase, dipeptidyl, IV, compd. with
     7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-
     (trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine (1:1) (9CI)
MF   C16 H15 F6 N5 O . Unspecified

     CM   1

Absolute stereochemistry.
```



CM 2

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L5 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2,4-Thiazolidinedione, 5-[[4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]phenyl]methyl]-, mixt. with (3R)-3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-1-butanone phosphate (1:1)
MF C20 H19 N3 O4 S . C16 H15 F6 N5 O . H3 O4 P
CI MXS

CM 1



CM 2

CM 3

Absolute stereochemistry.



CM 4



L5 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-
MF C16 H15 F6 N5 O
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l4 full
FULL SEARCH INITIATED 09:56:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 178 TO ITERATE

100.0% PROCESSED 178 ITERATIONS 58 ANSWERS
SEARCH TIME: 00.00.01

L6 58 SEA SSS FUL L4

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	372.24	372.46

FILE 'CAPLUS' ENTERED AT 09:56:57 ON 10 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Mar 2009 VOL 150 ISS 11
FILE LAST UPDATED: 9 Mar 2009 (20090309/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l6
L7         248 L6

=> s l6 and (pd<=20040116 or ad<=20040116 or prd<=20040116)
           248 L6
      24800856 PD<=20040116
                (PD<=20040116)
       4804725 AD<=20040116
                (AD<=20040116)
       4276669 PRD<=20040116
                (PRD<=20040116)
L8          18 L6 AND (PD<=20040116 OR AD<=20040116 OR PRD<=20040116)

=> d l8 1-18 ibib hitstr

L8   ANSWER 1 OF 18  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2005:1050865  CAPLUS
DOCUMENT NUMBER:         143:347172
TITLE:                   Preparation of imidazoles as inhibitors of glutaminyl
                         cyclase.
INVENTOR(S):             Schilling, Stephan; Buchholz, Mirko; Niestroj, Andre
                         Johannes; Heiser, Ulrich; Demuth, Hans-Ulrich
PATENT ASSIGNEE(S):      Probiodrug Ag, Germany
SOURCE:                  U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of U.S.
                         Ser. No. 838,993.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  8
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
     US 20050215573       A1    20050929    US 2005-51760            20050204
     US 7304086           B2    20071204
     US 20040224875       A1    20041111    US 2004-838993           20040505 <--
     US 7371871           B2    20080513
     US 20090018087       A1    20090115    US 2007-923307           20071024
PRIORITY APPLN. INFO.:                       US 2004-542133P      P   20040205
                                             US 2004-838993       A2  20040505
                                             US 2004-634364P      P   20041208
                                             US 2003-468014P      P   20030505 <--
                                             US 2005-51760        A1  20050204
OTHER SOURCE(S):         CASREACT 143:347172; MARPAT 143:347172
IT   654671-78-0, MK431
```

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of imidazoles as inhibitors of glutaminyl cyclase)

RN 654671-78-0 CAPLUS

CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:823672 CAPLUS
DOCUMENT NUMBER: 143:229851
TITLE: Preparation of imidazolyl thiourea derivatives as inhibitors of glutaminyl cyclase
INVENTOR(S): Schilling, Stephan; Buchholz, Mirko; Niestroj, Andre Johannes; Demuth, Hans-Ulrich; Heiser, Ulrich
PATENT ASSIGNEE(S): Probiodrug A.-G., Germany
SOURCE: PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005075436	A2	20050818	WO 2005-EP1153	20050204

WO 2005075436 A3 20051208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20040224875	A1	20041111	US 2004-838993		20040505 <--
US 7371871	B2	20080513			
AU 2005210004	A1	20050818	AU 2005-210004		20050204
CA 2554809	A1	20050818	CA 2005-2554809		20050204
EP 1713780	A2	20061025	EP 2005-707206		20050204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
CN 1918131	A	20070221	CN 2005-80004289		20050204
BR 2005007485	A	20070710	BR 2005-7485		20050204
JP 2007520520	T	20070726	JP 2006-551809		20050204
IN 2006KN02139	A	20070518	IN 2006-KN2139		20060728
MX 2006008868	A	20061030	MX 2006-8868		20060804
KR 2006125884	A	20061206	KR 2006-717874		20060901
PRIORITY APPLN. INFO.:			US 2004-542133P	P	20040205
			US 2004-838993	A	20040505
			US 2004-634364P	P	20041208
			US 2003-468014P	P	20030505 <--
			WO 2005-EP1153	W	20050204

OTHER SOURCE(S): CASREACT 143:229851; MARPAT 143:229851

IT 654671-78-0, MK-431
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed co-drugs; preparation of imidazolyl thiourea derivs. as inhibitors of glutaminyl cyclase)

RN 654671-78-0 CAPLUS

CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:729507 CAPLUS
DOCUMENT NUMBER: 143:216652
TITLE: Novel crystalline salts of a dipeptidyl peptidase-IV inhibitor
INVENTOR(S): Ferlita, Russell R.; Hansen, Karl; Vydra, Vicky K.; Wang, Yaling; Lindemann, Christopher M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005072530	A1	20050811	WO 2005-US951	20050112 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1708571	A1	20061011	EP 2005-705553	20050112 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
US 20080227786	A1	20080918	US 2006-585603	20060711 <--
PRIORITY APPLN. INFO.:			US 2004-537073P	P 20040116 <--
			WO 2005-US951	W 20050112

IT 486460-32-6P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(crystalline salts of dipeptidyl peptidase-IV inhibitor)
RN 486460-32-6 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 862156-86-3P 862156-87-4P 862156-90-9P
862156-92-1P 862156-93-2P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystalline salts of dipeptidyl peptidase-IV inhibitor)
RN 862156-86-3 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, benzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 862156-87-4 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 862156-90-9 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 3144-16-9

CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).



RN 862156-92-1 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, hydrochloride, hydrate (1:1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

● H2O

RN 862156-93-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, (2R,3R)-2,3-dihydroxybutanedioate, hydrate (2:2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



IT 486459-71-6 862156-85-2 862156-88-5
862156-89-6 862156-91-0
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crystalline salts of dipeptidyl peptidase-IV inhibitor)
RN 486459-71-6 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, hydrochloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 862156-85-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 862156-88-5 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, compd. with 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 5872-08-2
CMF C10 H16 O4 S



RN 862156-89-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



RN 862156-91-0 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1R,4S)-, compd. with 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6

CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 35963-20-3
CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:696517 CAPLUS
DOCUMENT NUMBER: 143:186770
TITLE: Glutaminyl cyclase inhibitors optionally combined with other agents for the treatment of neuronal disorders
INVENTOR(S): Schulz, Ingo; Schilling, Stephan; Niestroj, Andre Johannes; Heiser, Ulrich; Demuth, Hans-Ulrich; Rossner, Steffen
PATENT ASSIGNEE(S): Probiodrug AG, Germany
SOURCE: U.S. Pat. Appl. Publ., 70 pp., Cont.-in-part of U.S. Ser. No. 976,677.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050171112	A1	20050804	US 2004-2169	20041202 <--
US 20050137142	A1	20050623	US 2004-976677	20041029 <--
US 20060100253	A1	20060511	US 2005-290735	20051130 <--
WO 2006058720	A2	20060608	WO 2005-EP12765	20051130
WO 2006058720	A3	20060727		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

EP 1824846 A2 20070829 EP 2005-826439 20051130
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
JP 2008521853 T 20080626 JP 2007-543765 20051130
PRIORITY APPLN. INFO.: US 2003-516717P P 20031103 <--
US 2004-976677 A2 20041029
US 2004-2169 A2 20041202
US 2005-684137P P 20050524
WO 2005-EP12765 W 20051130

OTHER SOURCE(S): MARPAT 143:186770

IT 654671-78-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glutaminyl cyclase inhibitors optionally combined with other agents for treatment of neuronal disorders)

RN 654671-78-0 CAPLUS

CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



L8 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:493507 CAPLUS
DOCUMENT NUMBER: 143:43869
TITLE: Preparation of nitrogen containing bicyclic pyridine-based derivatives as inhibitors of HMG CoA reductase
INVENTOR(S): O'Connor, Stephen P.; Robl, Jeffrey; Ahmad, Saleem; Bisaha, Sharon; Murugesan, Natesan; Ngu, Khehyong; Shi, Yan; Stein, Philip D.; Soundararajan, Nachimuthu; Natalie, Kenneth J., Jr.; Kolla, Laxma R.; Sausker, Justin; Quinlan, Sandra L.; Fan, Junying; Petsch, Dejah; Guo, Zhenrong
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051386	A1	20050609	WO 2004-US39051	20041119 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050171140	A1	20050804	US 2004-989138	20041115 <--
US 7420059	B2	20080902		
EP 1684754	A1	20060802	EP 2004-811719	20041119 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				

PRIORITY APPLN. INFO.:

US 2003-523546P	P	20031120 <--
US 2004-989138	A	20041115
WO 2004-US39051	W	20041119

OTHER SOURCE(S): MARPAT 143:43869
IT 654671-78-0, MK 431
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed co-drug; preparation of nitrogen-containing bicyclic pyridine-based derivs. as inhibitors of HMG CoA reductase)
RN 654671-78-0 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:471999 CAPLUS
DOCUMENT NUMBER: 143:13357
TITLE: Combinations containing DPP IV inhibitors for treatment of obesity-related disorders
INVENTOR(S): Holmes, David Grenville
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049088	A2	20050602	WO 2004-EP12989	20041116 <--
WO 2005049088	A3	20051229		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

AU 2004290896	A1	20050602	AU 2004-290896		20041116 <--
CA 2545514	A1	20050602	CA 2004-2545514		20041116 <--
EP 1687030	A2	20060809	EP 2004-797931		20041116 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
BR 2004016627	A	20070116	BR 2004-16627		20041116 <--
CN 1901938	A	20070124	CN 2004-80040087		20041116 <--
JP 2007511486	T	20070510	JP 2006-538824		20041116 <--
KR 2006109912	A	20061023	KR 2006-709505		20060516 <--
MX 2006005596	A	20060811	MX 2006-5596		20060517 <--
IN 2006CN01727	A	20070810	IN 2006-CN1727		20060517 <--
US 20070149451	A1	20070628	US 2007-579580		20070125 <--
PRIORITY APPLN. INFO.:			US 2003-520564P	P	20031117 <--
			WO 2004-EP12989	W	20041116

IT 654671-78-0, MK-0431
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing DPP IV inhibitors for treatment of obesity-related disorders)

RN 654671-78-0 CAPLUS

CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:471952 CAPLUS
DOCUMENT NUMBER: 143:20035
TITLE: Combinations useful for the treatment of neuronal disorders
INVENTOR(S): Schulz, Ingo; Schilling, Stephan; Niestroj, Andre Johannes; Demuth, Hans-Ulrich; Rossner, Steffen
PATENT ASSIGNEE(S): Probiodrug A.G., Germany
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005049027	A2	20050602	WO 2004-EP12301		20041029 <--
WO 2005049027	A3	20060112			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004290499	A1	20050602	AU 2004-290499		20041029 <--
CA 2544573	A1	20050602	CA 2004-2544573		20041029 <--
EP 1680120	A2	20060719	EP 2004-791058		20041029 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
JP 2007509898	T	20070419	JP 2006-537220		20041029 <--
IN 2006KN01290	A	20070427	IN 2006-KN1290		20060516 <--
PRIORITY APPLN. INFO.:			US 2003-516717P	P	20031103 <--
			WO 2004-EP12301	W	20041029

OTHER SOURCE(S): MARPAT 143:20035
IT 654671-78-0, MK-0431
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dipeptidyl peptidase IV inhibitor; treatment of neuronal disorders using glutaminyl cyclase inhibitors in combination with other agents)
RN 654671-78-0 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:471947 CAPLUS
DOCUMENT NUMBER: 143:1284
TITLE: Use of organic compounds
INVENTOR(S): Pratley, Richard; Foley, James E.; Hughes, Thomas Edward
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049022	A2	20050602	WO 2004-EP12990	20041116 <--
WO 2005049022	A3	20050721		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004290897	A1	20050602	AU 2004-290897	20041116 <--
CA 2545641	A1	20050602	CA 2004-2545641	20041116 <--
EP 1686994	A2	20060809	EP 2004-797932	20041116 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

BR 2004016628	A	20070116	BR 2004-16628		20041116 <--
CN 1905876	A	20070131	CN 2004-80040508		20041116 <--
JP 2007511487	T	20070510	JP 2006-538825		20041116 <--
MX 2006005518	A	20060817	MX 2006-5518		20060516 <--
KR 2006109911	A	20061023	KR 2006-709502		20060516 <--
IN 2006CN01724	A	20070629	IN 2006-CN1724		20060517 <--
PRIORITY APPLN. INFO.:			US 2003-520562P	P	20031117 <--
			US 2003-520563P	P	20031117 <--
			US 2004-547191P	P	20040224
			US 2004-547192P	P	20040224
			WO 2004-EP12990	W	20041116

IT 654671-78-0, MK-0431
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(DPP-IV inhibitors for treatment of cardiovascular and renal diseases)
RN 654671-78-0 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:405417 CAPLUS
DOCUMENT NUMBER: 142:469248
TITLE: Pharmacetical compositions for enhanced absorption
INVENTOR(S): Wong, Patrick S. L.; Yan, Dong

PATENT ASSIGNEE(S): Alza Corporation, USA; Guittard, George V.
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2005041925	A2	20050512	WO 2004-US36040		20041029	<--
WO 2005041925	A3	20050929				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW						
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
AU 2004285533	A1	20050512	AU 2004-285533		20041029	<--
CA 2543238	A1	20050512	CA 2004-2543238		20041029	<--
US 20050158374	A1	20050721	US 2004-978141		20041029	<--
US 20050163848	A1	20050728	US 2004-978136		20041029	<--
US 20050163849	A1	20050728	US 2004-978137		20041029	<--
US 20050163841	A1	20050728	US 2004-978138		20041029	<--
US 20050165102	A1	20050728	US 2004-978139		20041029	<--
US 20060094782	A9	20060504				
US 20050163850	A1	20050728	US 2004-978252		20041029	<--
EP 1677757	A2	20060712	EP 2004-810118		20041029	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK						
CN 1901881	A	20070124	CN 2004-80039649		20041029	<--
JP 2007509973	T	20070419	JP 2006-538323		20041029	<--
MX 2006004957	A	20061207	MX 2006-4957		20060502	<--
IN 2006KN01135	A	20070427	IN 2006-KN1135		20060502	<--
KR 2006130571	A	20061219	KR 2006-710561		20060530	<--
NO 2006002504	A	20060721	NO 2006-2504		20060531	<--
PRIORITY APPLN. INFO.:			US 2003-516259P	P	20031031	<--
			US 2003-519509P	P	20031112	<--
			WO 2004-US36040	W	20041029	

IT 851476-07-8
RL: FMU (Formation, unclassified); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(pharmacetical compns. for enhanced absorption)
RN 851476-07-8 CAPLUS
CN 9-Octadecenamide, N-[(1R)-3-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]-, (9Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 486460-32-6
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacetical compns. for enhanced absorption)
RN 486460-32-6 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:300188 CAPLUS
DOCUMENT NUMBER: 142:360851
TITLE: Novel crystalline form of a phosphate salt of a dipeptidyl peptidase-IV inhibitor
INVENTOR(S): Chen, Alex M.; Wenslow, Robert M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030127	A2	20050407	WO 2004-US30434	20040917 <--
WO 2005030127	A3	20050526		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

EP 1667524 A2 20060614 EP 2004-784324 20040917 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

US 20070021430 A1 20070125 US 2006-570409 20060303 <--

PRIORITY APPLN. INFO.: US 2003-505118P P 20030923 <--
WO 2004-US30434 W 20040917

IT 654671-77-9P 654671-78-0P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystalline form of phosphate salt of dipeptidyl peptidase-IV inhibitor)

RN 654671-77-9 CAPLUS

CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate, hydrate (1:1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



RN 654671-78-0 CAPLUS

CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



IT 486460-32-6P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(crystalline form of phosphate salt of dipeptidyl peptidase-IV inhibitor)
RN 486460-32-6 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:216618 CAPLUS
DOCUMENT NUMBER: 142:303604
TITLE: Novel crystal forms of a dihydrogen phosphate salt of a trizolopyrazine dipeptidyl peptidase IV inhibitor

INVENTOR(S): Wenslow, Robert M.; Armstrong, Joseph D., III; Chen, Alex M.; Cypes, Stephen; Ferlita, Russell R.; Hansen, Karl; Lindemann, Christopher M.; Spartalis, Evangelia

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020920	A2	20050310	WO 2004-US27983	20040827 <--
WO 2005020920	A3	20050428		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004268024	A1	20050310	AU 2004-268024	20040827 <--
AU 2004268024	B2	20070712		
CA 2536251	A1	20050310	CA 2004-2536251	20040827 <--
EP 1662876	A2	20060607	EP 2004-782460	20040827 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1845674	A	20061011	CN 2004-80025043	20040827 <--
JP 2007504230	T	20070301	JP 2006-525371	20040827 <--
US 20060287528	A1	20061221	US 2006-569566	20060227 <--
IN 2006DN01130	A	20070817	IN 2006-DN1130	20060302 <--
PRIORITY APPLN. INFO.:			US 2003-499629P P	20030902 <--
			WO 2004-US27983 W	20040827

OTHER SOURCE(S): CASREACT 142:303604

IT 486460-32-6P 654671-78-0P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystal forms of a trizolopyrazine dihydrogen phosphate salt dipeptidyl peptidase IV inhibitor)

RN 486460-32-6 CAPLUS

CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 654671-78-0 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



IT 847445-75-4 847445-76-5 847445-77-6
847445-78-7 847445-79-8 847445-80-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crystal forms of a trizolopyrazine dihydrogen phosphate salt dipeptidyl peptidase IV inhibitor)
RN 847445-75-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate, compd. with 2-propanone (1:1:?) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



CM 3

CRN 67-64-1
CMF C3 H6 O



RN 847445-76-5 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate, compd. with acetonitrile (1:1:?) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



CM 3

CRN 75-05-8
CMF C2 H3 N



RN 847445-77-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate, compd. with methanol (1:1:?) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



CM 3

CRN 67-56-1
CMF C H4 O



RN 847445-78-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate, compd. with ethanol (1:1:?) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



CM 3

CRN 64-17-5
CMF C2 H6 O



RN 847445-79-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate,

compd. with 1-propanol (1:1:?) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



CM 3

CRN 71-23-8
CMF C3 H8 O

$H_3C-CH_2-CH_2-OH$

RN 847445-80-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate, compd. with 2-propanol (1:1:?) (9CI) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



CM 3

CRN 67-63-0
CMF C3 H8 O



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:29336 CAPLUS
DOCUMENT NUMBER: 142:114455
TITLE: Preparation of phosphoric acid salt of a β-amino acid amide dipeptidyl peptidase-IV inhibitor and its monohydrate
INVENTOR(S): Cypes, Stephen Howard; Chen, Alex Minhua; Ferlita, Russell R.; Hansen, Karl; Lee, Ivan; Vydra, Vicky K.; Wenslow, Robert M., Jr.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005003135	A1	20050113	WO 2004-US19683	20040618 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004253889	A1	20050113	AU 2004-253889	20040618	<--
AU 2004253889	B2	20080424			
CA 2529400	A1	20050113	CA 2004-2529400	20040618	<--
CA 2529400	C	20071009			
EP 1654263	A1	20060510	EP 2004-755691	20040618	<--
EP 1654263	B1	20070912			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
JP 2006516268	T	20060629	JP 2005-518292	20040618	<--
BR 2004011726	A	20060808	BR 2004-11726	20040618	<--
CN 1832949	A	20060913	CN 2004-80017544	20040618	<--
CN 100430397	C	20081105			
AT 373003	T	20070915	AT 2004-755691	20040618	<--
ES 2291907	T3	20080301	ES 2004-755691	20040618	<--
IL 172563	A	20080708	IL 2004-172563	20040618	<--
NZ 544026	A	20080829	NZ 2004-544026	20040618	<--
US 20050032804	A1	20050210	US 2004-874992	20040623	<--
US 7326708	B2	20080205			
MX 2005013931	A	20060224	MX 2005-13931	20051219	<--
IN 2005DN05948	A	20080509	IN 2005-DN5948	20051220	<--
NO 2006000362	A	20060323	NO 2006-362	20060123	<--
KR 2008022232	A	20080310	KR 2008-702869	20080201	<--
PRIORITY APPLN. INFO.:			US 2003-482161P	P 20030624	<--
			WO 2004-US19683	W 20040618	
			KR 2005-724825	A3 20051223	

IT 654671-77-9P, (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine dihydrogen phosphate monohydrate
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(DPPIV inhibitor; preparation of triazolopyrazine beta amino amide dihydrogenphosphates and their monohydrates as peptidase-iv inhibitor)

RN 654671-77-9 CAPLUS

CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate, hydrate (1:1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



IT 486460-32-6P, (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of triazolopyrazine beta amino amide dihydrogenphosphates and their monohydrates as peptidase-iv inhibitor)
RN 486460-32-6 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 654671-78-0P 823817-58-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolopyrazine beta amino amide dihydrogenphosphates and their monohydrates as peptidase-iv inhibitor)
RN 654671-78-0 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



RN 823817-58-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3S)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 823817-55-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2

CMF H3 O4 P



IT 823817-55-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of triazolopyrazine beta amino amide dihydrogenphosphates and their monohydrates as peptidase-iv inhibitor)
RN 823817-55-6 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1124587 CAPLUS
DOCUMENT NUMBER: 142:69188
TITLE: Combination therapy for the treatment of diabetes
INVENTOR(S): Erondu, Ngozi E.; Fong, Tung M.; MacNeil, Douglas J.; Van Der Ploeg, Leonardus H. T.; Kanatani, Akio
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd.
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110375	A2	20041223	WO 2004-US17291	20040602 <--
WO 2004110375	A3	20050512		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1635832 A2 20060322 EP 2004-753999 20040602 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

US 20070099884 A1 20070503 US 2005-559206 20051202 <--

PRIORITY APPLN. INFO.: US 2003-476388P P 20030606 <--
WO 2004-US17291 W 20040602

OTHER SOURCE(S): MARPAT 142:69188

IT 486459-97-6 486460-32-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dipeptidyl peptidase IV inhibitor; combination therapy of diabetes and diabetes-related disorders using antiobesity agent and antidiabetic agent and other agents)

RN 486459-97-6 CAPLUS

CN 1-Butanone, 3-amino-4-(4-bromo-2,5-difluorophenyl)-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 486460-32-6 CAPLUS

CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:964805 CAPLUS

DOCUMENT NUMBER: 141:388745

TITLE: Preparation of glutaminyl cyclase inhibitors for use in treating neurological diseases

INVENTOR(S): Schilling, Stephan; Niestroj, Andre J.; Heiser, Ulrich; Buchholz, Mirko; Demuth, Hans-Ulrich

PATENT ASSIGNEE(S): Probiodrug AG, Germany
SOURCE: U.S. Pat. Appl. Publ., 34 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20040224875	A1	20041111	US 2004-838993		20040505	<--
US 7371871	B2	20080513				
WO 2004098591	A2	20041118	WO 2004-EP4773		20040505	<--
WO 2004098591	A3	20050331				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW						
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
EP 1620091	A2	20060201	EP 2004-731158		20040505	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK						
JP 2006525276	T	20061109	JP 2006-505375		20040505	<--
EP 1961416	A1	20080827	EP 2007-150046		20040505	<--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR						
AU 2005210004	A1	20050818	AU 2005-210004		20050204	
CA 2554809	A1	20050818	CA 2005-2554809		20050204	
WO 2005075436	A2	20050818	WO 2005-EP1153		20050204	
WO 2005075436	A3	20051208				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM						
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
US 20050215573	A1	20050929	US 2005-51760		20050204	
US 7304086	B2	20071204				
EP 1713780	A2	20061025	EP 2005-707206		20050204	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS						
CN 1918131	A	20070221	CN 2005-80004289		20050204	
BR 2005007485	A	20070710	BR 2005-7485		20050204	
JP 2007520520	T	20070726	JP 2006-551809		20050204	
MX 2006008868	A	20061030	MX 2006-8868		20060804	
KR 2006125884	A	20061206	KR 2006-717874		20060901	
US 20090018087	A1	20090115	US 2007-923307		20071024	
US 20080153892	A1	20080626	US 2008-46520		20080312	<--
US 20080286810	A1	20081120	US 2008-101497		20080411	<--
PRIORITY APPLN. INFO.:			US 2003-468014P	P	20030505	<--
			US 2003-468043P	P	20030505	<--

US 2003-512038P	P	20031015	<--
US 2004-542133P	P	20040205	
EP 2004-731150	A3	20040505	
US 2004-838993	A	20040505	
US 2004-839017	A3	20040505	
WO 2004-EP4773	W	20040505	
US 2004-634364P	P	20041208	
US 2005-51760	A1	20050204	
WO 2005-EP1153	W	20050204	

OTHER SOURCE(S): MARPAT 141:388745

IT 654671-78-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combination chemotherapy; preparation of glutaminyl cyclase inhibitors for use in treating neurol. diseases)

RN 654671-78-0 CAPLUS

CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 486460-32-6
CMF C16 H15 F6 N5 O

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



REFERENCE COUNT: 347 THERE ARE 347 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:857554 CAPLUS
DOCUMENT NUMBER: 141:314625
TITLE: Process for the preparation of β-amino acid amide dipeptidyl peptidase-IV inhibitors

INVENTOR(S): Angelaud, Remy; Armstrong, Joseph D., III; Askin, David; Balsells, Jaume; Hansen, Karl; Lee, Jaemoon; Maligres, Peter E.; Rivera, Nelo R.; Xiao, Yi; Zhong, Yong-Li
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087650	A2	20041014	WO 2004-US8826	20040323 <--
WO 2004087650	A3	20050113		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-457976P P 20030327 <--
OTHER SOURCE(S): CASREACT 141:314625; MARPAT 141:314625
IT 486460-32-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for preparation of triazolopyrazine β-amino acyl derivs. as dipeptidyl peptidase-IV inhibitors)
RN 486460-32-6 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:824045 CAPLUS
DOCUMENT NUMBER: 141:332476
TITLE: Process for preparation of chiral β-amino acid derivatives
INVENTOR(S): Dreher, Spencer D.; Ikemoto, Norihiro; Njolito, Eugenia; Rivera, Nelo R.; Tellers, David M.; Xiao, Yi

PATENT ASSIGNEE(S): Merck & Co., Inc, USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085661	A2	20041007	WO 2004-US8533	20040319 <--
WO 2004085661	A3	20050310		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-457128P P 20030324 <--
US 2003-511210P P 20031015 <--

OTHER SOURCE(S): CASREACT 141:332476; MARPAT 141:332476

IT 769195-20-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(asym. synthesis of chiral β-amino acid derivs. via addition of phenylglycine amide to triazolopyrazinyl β-ketoesters, followed by catalytic hydrogenation of enamines and catalytic hydrogenolysis)

RN 769195-20-2 CAPLUS

CN Benzeneacetamide, α-[[(1R)-3-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 486460-32-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(asym. synthesis of chiral β-amino acid derivs. via addition of phenylglycine amide to triazolopyrazinyl β-ketoesters, followed by catalytic hydrogenation of enamines and catalytic hydrogenolysis)

RN 486460-32-6 CAPLUS

CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:817850 CAPLUS
DOCUMENT NUMBER: 141:314350
TITLE: Process for the preparation of chiral β-amino acid derivatives by asymmetric hydrogenation of enamino esters and amides using transition-metal complexed chiral ferrocenyldiphosphines.
INVENTOR(S): Xiao, Yi; Armstrong, Joseph D., III; Krska, Shane W.; Njolito, Eugenia; Rivera, Nelo R.; Sun, Yongkui; Rosner, Thorsten
PATENT ASSIGNEE(S): Merck & Co. Inc., USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085378	A1	20041007	WO 2004-US7793	20040315 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004223885	A1	20041007	AU 2004-223885	20040315 <--
CA 2518435	A1	20041007	CA 2004-2518435	20040315 <--
EP 1606243	A1	20051221	EP 2004-720790	20040315 <--
EP 1606243	B1	20080709		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1761642	A	20060419	CN 2004-80007313	20040315 <--
CN 100339354	C	20070926		
JP 2006521354	T	20060921	JP 2006-507177	20040315 <--
AT 400545	T	20080715	AT 2004-720790	20040315 <--
ES 2307000	T3	20081116	ES 2004-720790	20040315 <--
IN 2005DN03930	A	20070824	IN 2005-DN3930	20050902 <--

US 20060194977 A1 20060831 US 2005-549425 20050915 <--
US 7468459 B2 20081223
PRIORITY APPLN. INFO.: US 2003-455932P P 20030319 <--
WO 2004-US7793 A 20040315
OTHER SOURCE(S): CASREACT 141:314350; MARPAT 141:314350
IT 486460-32-6P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of chiral β-amino acid derivs. by asym. hydrogenation of enamino esters and amides using transition-metal complexed chiral ferrocenyldiphosphines)
RN 486460-32-6 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:42275 CAPLUS
DOCUMENT NUMBER: 138:106717
TITLE: Preparation of β-amino tetrahydroimidazo[1,2-a]pyrazines and tetrahydrotrioazolo[4,3-a]pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
INVENTOR(S): Edmondson, Scott D.; Fisher, Michael H.; Kim, Dooseop; MacCoss, Malcolm; Parmee, Emma R.; Weber, Ann E.; Xu, Jinyou
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004498	A1	20030116	WO 2002-US21349	20020705 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,

PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2450740	A1	20030116	CA 2002-2450740		20020705	<--
CA 2450740	C	20060214				
AU 2002320303	A1	20030121	AU 2002-320303		20020705	<--
AU 2002320303	B2	20041014				
US 20030100563	A1	20030529	US 2002-189603		20020705	<--
US 6699871	B2	20040302				
EP 1412357	A1	20040428	EP 2002-749813		20020705	<--
EP 1412357	B1	20060322				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK						
BR 2002010866	A	20040629	BR 2002-10866		20020705	<--
CN 1524082	A	20040825	CN 2002-813558		20020705	<--
CN 1290848	C	20061220				
HU 2004001104	A2	20040928	HU 2004-1104		20020705	<--
HU 2004001104	A3	20060228				
HU 225695	B1	20070628				
JP 2004536115	T	20041202	JP 2003-510665		20020705	<--
JP 3762407	B2	20060405				
TW 226331	B	20050111	TW 2002-91114990		20020705	<--
NZ 529833	A	20050128	NZ 2002-529833		20020705	<--
EP 1625847	A1	20060215	EP 2005-77584		20020705	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK						
AT 321048	T	20060415	AT 2002-749813		20020705	<--
PT 1412357	T	20060731	PT 2002-749813		20020705	<--
ES 2259713	T3	20061016	ES 2002-749813		20020705	<--
CN 1861077	A	20061115	CN 2006-10077691		20020705	<--
IL 159109	A	20070603	IL 2002-159109		20020705	<--
PL 196278	B1	20071231	PL 2002-367279		20020705	<--
ZA 2003009294	A	20040722	ZA 2003-9294		20031128	<--
US 20040167133	A1	20040826	US 2003-481353		20031219	<--
US 7125873	B2	20061024				
BG 108493	A	20050430	BG 2003-108493		20031222	<--
NO 321999	B1	20060731	NO 2004-21		20040105	<--
IN 2004CN00026	A	20051202	IN 2004-CN26		20040106	<--
MX 2004000018	A	20040521	MX 2004-18		20040107	<--
HK 1068882	A1	20070504	HK 2005-101300		20050216	<--
US 20060270679	A1	20061130	US 2006-500252		20060807	<--
PRIORITY APPLN. INFO.:			US 2001-303474P	P	20010706	<--
			CN 2002-813558	A3	20020705	<--
			EP 2002-749813	A3	20020705	<--
			WO 2002-US21349	W	20020705	<--
			US 2003-481353	A1	20031219	<--

OTHER SOURCE(S): MARPAT 138:106717

IT 486459-71-6P 486459-97-6P 486460-32-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of β-amino tetrahydroimidazo[1,2-a]pyrazines and tetrahydrotrioazolo[4,3-a]pyrazines as dipeptidyl peptidase inhibitors)

RN 486459-71-6 CAPLUS

CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, hydrochloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 486459-97-6 CAPLUS
CN 1-Butanone, 3-amino-4-(4-bromo-2,5-difluorophenyl)-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 486460-32-6 CAPLUS
CN 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 486460-23-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of β-amino tetrahydroimidazo[1,2-a]pyrazines and tetrahydrotrioazolo[4,3-a]pyrazines as dipeptidyl peptidase inhibitors)
RN 486460-23-5 CAPLUS
CN Carbamic acid, [(1R)-3-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-

a]pyrazin-7(8H)-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	81.24	453.70

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:02:05 ON 10 MAR 2009